These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18494811)

  • 1. Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients.
    Masuda H; Sakamoto M; Irie J; Kitaoka A; Shiono K; Inoue G; Atsuda K; Yamada S
    Diabetes Obes Metab; 2008 Dec; 10(12):1261-5. PubMed ID: 18494811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of twice-daily injections of premixed insulin analog on glycemic control in type 2 diabetic patients.
    Shimizu H; Monden T; Matsumura M; Domeki N; Kasai K
    Yonsei Med J; 2010 Nov; 51(6):845-9. PubMed ID: 20879049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes.
    Sargin H; Sargin M; Altuntaş Y; Sengül AM; Orbay E; Seber S; Uçak S; Yayla A
    Diabetes Res Clin Pract; 2003 Nov; 62(2):79-86. PubMed ID: 14581144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
    Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
    Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.
    Roach P; Trautmann M; Arora V; Sun B; Anderson JH
    Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
    Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G;
    Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of BMI, Age and duration of diabetes mellitus on glycaemic control with twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart (JDDM 18): retrospective reanalysis of a 6-month, randomized, open-label, multicentre trial in Japan.
    Arai K; Hirao K; Yamauchi M; Takagi H; Kobayashi M;
    Clin Drug Investig; 2010; 30(1):35-40. PubMed ID: 19995096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure.
    Altuntas Y; Ozen B; Ozturk B; Sengul A; Ucak S; Ersoy O; Karul S
    Diabetes Obes Metab; 2003 Nov; 5(6):371-8. PubMed ID: 14617222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure.
    Miyashita Y; Nishimura R; Nemoto M; Matsudaira T; Kurata H; Yokota T; Yokota K; Tojo K; Utsunomiya K; Tajima N
    Cardiovasc Diabetol; 2008 May; 7():16. PubMed ID: 18507868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin.
    Herz M; Arora V; Sun B; Ferguson SC; Bolli GB; Frier BM
    Diabet Med; 2002 Nov; 19(11):917-23. PubMed ID: 12421428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.
    Fujii H; Watanabe Y; Ueki A; Ohno A; Kato M; Kondo K; Takamura H; Takesue M; Nishimura H; Matsuda D; Miyakawa T
    Int J Clin Pract; 2010 Oct; 64(11):1512-1519. PubMed ID: 20678116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
    Vignati L; Anderson JH; Iversen PW
    Clin Ther; 1997; 19(6):1408-21. PubMed ID: 9444449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
    Giugliano D; Ceriello A; Razzoli E; Esposito K
    Clin Drug Investig; 2008; 28(4):199-210. PubMed ID: 18345710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.